Escherichia coli NADH dehydrogenase I, a minimal form of the mitochondrial complex I

1993 ◽  
Vol 21 (4) ◽  
pp. 998-1001 ◽  
Author(s):  
Hans Leif ◽  
Uwe Weidner ◽  
Annette Berger ◽  
Volker Spehr ◽  
Matthias Braun ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Complex I ◽  
Nadh Dehydrogenase ◽  
Mitochondrial Complex I ◽  
Mitochondrial Complex ◽  
Minimal Form

scholarly journals Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis

eLife ◽  
2014 ◽  
Vol 3 ◽  
Author(s):  
William W Wheaton ◽  
Samuel E Weinberg ◽  
Robert B Hamanaka ◽  
Saul Soberanes ◽  
Lucas B Sullivan ◽  
...  
Keyword(s):  
Cancer Cells ◽  
Cancer Progression ◽  
Complex I ◽  
Nadh Dehydrogenase ◽  
Cellular Proliferation ◽  
Human Cancer ◽  
Cellular Respiration ◽  
Mitochondrial Complex I ◽  
Mitochondrial Complex ◽  
Human Cancer Cells

Recent epidemiological and laboratory-based studies suggest that the anti-diabetic drug metformin prevents cancer progression. How metformin diminishes tumor growth is not fully understood. In this study, we report that in human cancer cells, metformin inhibits mitochondrial complex I (NADH dehydrogenase) activity and cellular respiration. Metformin inhibited cellular proliferation in the presence of glucose, but induced cell death upon glucose deprivation, indicating that cancer cells rely exclusively on glycolysis for survival in the presence of metformin. Metformin also reduced hypoxic activation of hypoxia-inducible factor 1 (HIF-1). All of these effects of metformin were reversed when the metformin-resistant Saccharomyces cerevisiae NADH dehydrogenase NDI1 was overexpressed. In vivo, the administration of metformin to mice inhibited the growth of control human cancer cells but not those expressing NDI1. Thus, we have demonstrated that metformin's inhibitory effects on cancer progression are cancer cell autonomous and depend on its ability to inhibit mitochondrial complex I.

Trichomonas hydrogenosomes contain the NADH dehydrogenase module of mitochondrial complex I

Nature ◽  
2004 ◽  
Vol 432 (7017) ◽  
pp. 618-622 ◽  
Author(s):  
Ivan Hrdy ◽  
Robert P. Hirt ◽  
Pavel Dolezal ◽  
Lucie Bardonová ◽  
Peter G. Foster ◽  
...  
Keyword(s):  
Complex I ◽  
Nadh Dehydrogenase ◽  
Mitochondrial Complex I ◽  
Mitochondrial Complex

scholarly journals Novel mitochondrial complex I-inhibiting peptides restrain NADH dehydrogenase activity

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Yao-Peng Xue ◽  
Mou-Chieh Kao ◽  
Chung-Yu Lan
Keyword(s):  
Antimicrobial Peptides ◽  
Complex I ◽  
Fungal Pathogens ◽  
Nadh Dehydrogenase ◽  
Mitochondrial Complex I ◽  
Mitochondrial Complex ◽  
Human Fungal Pathogen ◽  
New Class ◽  
Transport Chain ◽  
Nadh Dehydrogenases

Abstract The emergence of drug-resistant fungal pathogens is becoming increasingly serious due to overuse of antifungals. Antimicrobial peptides have potent activity against a broad spectrum of pathogens, including fungi, and are considered a potential new class of antifungals. In this study, we examined the activities of the newly designed peptides P-113Du and P-113Tri, together with their parental peptide P-113, against the human fungal pathogen Candida albicans. The results showed that these peptides inhibit mitochondrial complex I, specifically NADH dehydrogenase, of the electron transport chain. Moreover, P-113Du and P-113Tri also block alternative NADH dehydrogenases. Currently, most inhibitors of the mitochondrial complex I are small molecules or artificially-designed antibodies. Here, we demonstrated novel functions of antimicrobial peptides in inhibiting the mitochondrial complex I of C. albicans, providing insight in the development of new antifungal agents.

Sign in / Sign up

Export Citation Format

Share Document